Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237157 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer
A Phase 1 study, sponsored by RenovoRx.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02237157: Completed Phase 1 study, sponsored by RenovoRx.
NCT02237157 is a Phase 1 study that has completed, run by RenovoRx. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02237157, a Phase 1 study, has completed, sponsored by RenovoRx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.
Primary Outcome
Maximum Tolerated Dose (MTD) of gemcitabine administered intra-arterially to the pancreatic tumor(s) using the RenovoCath™ RC120 catheter. One week post treatment, toxicities will be assessed to determine if there is a pre-defined Dose Limiting Toxicity necessitating dose stopping or holding.
Interventions
- DRUG Gemcitabine, local delivery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
What the finished NCT02237157 record still lists
NCT02237157 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, local delivery is the first listed.
NCT02237157 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02237157 about?
NCT02237157 is a clinical study titled "A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer". A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.
What is the current status of trial NCT02237157?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-03. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02237157?
The interventions under investigation include: Gemcitabine, local delivery (DRUG).
Who is sponsoring clinical trial NCT02237157?
This trial is sponsored by RenovoRx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02237157's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia